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Abstract
Introduction: The objectives of our study were to investigate whether fibroblast growth factor-21 (FGF-21) is involved in short-term 
regulation of glucose and the change of FGF-21 after metformin use in diabetic subjects.
Material and methods: 43 subjects were recruited in the study, including 27 new-onset type 2 diabetes patients (nT2DM). A 75 g oral 
glucose tolerance test (OGTT) was administered to them. Blood samples were taken at 0, 60 ,120 and 180 minute of OGTT. nT2DM subjects 
were invited for further investigation, metformin was administered in a dose of 1.0 g every day for 1 week.
Results: Plasma FGF-21 changed significantly in the nT2DM group during the OGTT administration but not in the control group. No 
gender differences were observed at different time points in FGF-21 levels (p < 0.05). Administration of metformin for nT2DM resulted 
in a significant decrease in both glucose and FGF-21 at all OGTT times and in insulin at 60 min and 180 min, indicative of a decrease in 
HOMA-IR.
Conclusion: FGF-21 does not seem to be involved in short-term regulation of glycaemia in human subjects, and the change in OGTT 
delayed in T2DM. FGF-21 may participate in the processing of metformin, improving glucose and insulin sensitivity. 
(Pol J Endocrinol 2013; 64 (3): 220–224)
Key words: fibroblast growth factor-21, type 2 diabetes, OGTT, metformin
Streszczenie
Wstęp: Badanie przeprowadzono w celu ustalenia, czy czynnik wzrostu fibroblastów-21 (FGF-21) uczestniczy w regulacji stężenia glukozy 
i czy zastosowanie metforminy u chorych na cukrzycę wpływa na stężenie FGF-21.
Materiał i metody: Do badania włączono 43 osoby, w tym 27 chorych z nowo rozpoznaną cukrzycą typu 2 (nT2DM). U wszystkich prze-
prowadzono test doustnego obciążenia 75 g glukozy (OGTT). Próbki krwi pobrano w 0., 60.,120. i 180. minucie testu. Osobom z nT2DM 
zaproponowano udział w dalszych badaniach; zastosowano u nich metforminę w dawce 1,0 g/dobę przez tydzień.
Wyniki: Zmiany stężenia FGF-21 w osoczu podczas OGTT zaobserwowano tylko w grupie chorych na nT2DM; w grupie kontrolnej stężenie 
FGF-21 pozostało niezmienione. Nie stwierdzono, by stężenia FGF-21 w poszczególnych punktach czasowych różniły się w zależności od płci 
badanych (p < 0,05). Zastosowanie metforminy u osób z nT2DM spowodowało istotne zmniejszenie stężeń glukozy i FGF-21 we wszystkich 
punktach czasowych OGTT oraz zmniejszenie stężenia insuliny w 60. i 180. minucie, co wskazuje na obniżenie wskaźnika HOMA-IR.
Wnioski: FGF-21 nie uczestniczy w krótkoterminowej regulacji glikemii u ludzi, a zmiany jego stężenia podczas OGTT są opóźnione 
w T2DM. Być może FGF-21 bierze udział w metabolizowaniu metforminy, zwiększając wrażliwość na glukozę i insulinę. 
(Endokrynol Pol 2013; 64 (3): 220–224)
Słowa kluczowe: czynnik wzrostu fibroblastów-21, cukrzyca typu 2, OGTT, metformina
Introduction
Fibroblast growth factor-21, which is secreted by he-
patic cells, has been proposed as a potent metabolic 
regulator in glucose and lipid metabolism. FGF-21 can 
improve glucose uptake in 3T3-L1 adipocytes, reduce 
blood glucose and triglyceride levels, and prevent over-
expressed transgenic mice from obesity [1]. Moreover, 
FGF-21 can reverse hepatic steatosis and insulin resist-
ance, and reduce bodyweight [2]. It has been reported 
that FGF-21 caused significant improvements in fasting 
plasma glucose and lipoprotein profiles in diabetic 
monkeys [3]. FGF-21 treated mice exhibited increased 
energy expenditure, fat utilisation and lipid excretion, 
reduced hepatic steatosis and ameliorated glycaemia [4]. 
Chen et al. [5] suggested that plasma FGF-21 levels 
participated in the pathogenesis of newly diagnosed 
patients with type 2 diabetes mellitus. A recent study 
221
Endokrynologia Polska 2013; 64 (3)
PR
A
C
E 
O
R
Y
G
IN
A
LN
E
showed that FGF-21 was associated with abdominal 
obesity [6], correlated to serum adiponectin levels in 
subjects with type 2 diabetes [7], and influenced by 
BMI, fasting glycaemia, uric acid, and physical activ-
ity in healthy blue-collar workers [8]. But common to 
all these studies was that plasma FGF-21 levels were 
only assessed at one time-point. To date, there have 
been no published studies on the change of FGF-21 
after glucose load. The primary aim of our study is 
to determine whether FGF-21 levels change after 
glucose load.
Metformin is currently the most widely used drug 
worldwide in the treatment of diabetes and reducing 
insulin resistance in humans. However, it is not clear 
whether the mechanisms of treatment include the 
FGF-21 signalling pathway. Therefore we have also 
endeavoured to find out the reflection of FGF-21 levels 
after metformin therapy for diabetes.
Material and methods
Fourty three subjects were involved in our study and 
divided into two groups. The first group of 27 subjects 
(16 females, 11 males) was new-onset type 2 diabetes 
patients (nT2DM), who were recruited from the diabe-
tes specialist clinics (West China Hospital), aged 49.9 ± 
± 10.9 years, BMI 24.62 ± 2.04 kg/m2. The second group 
of 16 healthy volunteers (seven males, nine females) 
was recruited from among medical staff at West China 
Hospital, aged 46.75 ± 8.52 years, BMI 22.71 ± 3.00 kg/m2. 
The diagnosis of diabetes was based on 1999 World 
Health Organisation criteria (fasting plasma glucose level 
≥ 7.0 mmol/L or 2-h OGTT plasma glucose level 
≥ 11.1 mmol/L). A 75 g oral glucose tolerance test (OGTT) 
was performed for all subjects, plasma samples were 
taken before (0 minute) and at 60, 120, and 180 minutes 
after OGTT to detect glucose, insulin, and FGF-21.
The nT2DM group was administered metformin 
(glucophage) (0.5 g, twice a day) for one week. Plasma 
concentrations of glucose, insulin, and FGF-21 were 
measured.
All studies were approved by the Ethics Committee 
at West China Hospital, Sichuan University. Informed 
consent was obtained from all subjects before partici-
pation.
Height, weight, and waist circumference were meas-
ured after fasting by the same physician. Plasma glucose 
was determined by Roche DDP. Plasma insulin was 
measured by electro-chemiluminescence immunoassay 
(Roche E170). Plasma FGF-21 levels were determined 
by RIA (Phoenix Pharmaceuticals, Inc, USA) using 125I-
labelled FGF-21 as tracer. Blood samples were collected 
with aprotinin (0.6 TIU/ml of blood) and detection was 
centralised.
FGF-21 antibody was rabbit anti-human FGF-21 IgG, 
which is specific for human FGF-21. There are no cross-
reactions between FGF-21 antibody and human FGF-6, 
FGF-10, FGF-18, FGF-19, FGF-20, adiponectin, visfatin, 
leptin, or retinol-binding protein –4 resistin. The linear 
range is 0.5~8.5 ng/mL, intra-assay coefficient of varia-
tion (CV) < 5%, and inter-CV < 14%.
The formula for the homeostasis model assessment 
is as follows: homeostasis model assessment insulin 
resistance (HOMA-IR) = {(fasting insulin [μU/mL] × 
fasting glucose [mmol/L]}/22.5 [9].
Statistical analysis
The normal distribution of data was expressed as 
mean ± standard deviation, and the skewed distribu-
tion of information was expressed as median (quartile). 
T-tests were used to compare continuous variables 
normal distribution of data, while skewed distribution 
of information was compared using Mann-Whitney-U 
tests. Repeat measure analysis was used to compare the 
data at different times of OGTT. Pair sample t-test or 
2-related sample signed ranks test was used to compare 
differences before and after metformin. All statistical 
analyses were performed using SPSS v. 16.0 package 
for Windows. p < 0.05 was considered statistically 
significant.
Results
FGF-21 level changes in OGTT
No significant differences in FGF-21 levels were ob-
served between the control and nT2DM group at any 
OGTT time, whereas glucose levels differed at all time 
points, and insulin levels at 120 minutes and 180 min-
utes (Table I). Plasma FGF-21 changed significantly in 
the nT2DM group during the OGTT administration, 
but not in the control group. No gender differences 
were observed at any OGTT time point in control or 
patient groups.
FGF-21 level changes before and after metformin 
administration in nT2DM
Administration of metformin for one week resulted 
in a significant decrease in both glucose and FGF-21 
at all OGTT times and in insulin at 60 and 180 min-
utes OGTT, indicative of a decrease in HOMA-IR, 
as shown in Table II. Plasma FGF-21 decreased after 
one week of metformin treatment, although not in 
all individuals. When the subjects were divided into 
a male group and a female group, serum FGF-21 levels 
decreased after one week of metformin treatment in 
the female group at different times of OGTT (p < 0.05), 
but differences were not noted in the male group 
(data not shown).
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Discussion
Fibroblast growth factor-21 is a novel metabolic regu-
lator with multiple beneficial effects on glucose and 
insulin resistance in animal models and humans [10–12]. 
A significant positive correlation has been observed 
with obesity, metabolic syndrome [13] and type 2 diabe-
tes [14], but the mechanism of FGF-21 is unclear. Here, 
we have sought to address whether FGF-21 might be 
involved in short-term (i.e. postprandial) regulation of 
glycaemia in humans and whether metformin affects 
FGF-21 levels.
Our study demonstrated that the circulating FGF-21 
was opposite to insulin and glucose during the oral 
glucose tolerance test in humans. The mode of action 
for FGF-21 requires glucose transporters 1 (GLUT1) 
transcriptional activation. In contrast to the rapid re-
sponse elicited by insulin, the predominant effect of 
FGF-21 on glucose uptake required at least 2–4 hours 
of cell treatment [1].We found FGF-21 increased at 120 
and 180 minutes of OGTT in control by trend, and 
Table I. Descriptive statistics for the levels of glucose, insulin and FGF-21 during OGTT in T2DM and control group
Tabela I. Statystyki opisowe stężeń glukozy, insuliny i czynnika wzrostu fibroblastów-21 podczas doustnego testu tolerancji 
glukozy u chorych na cukrzycę typu 2 oraz w grupie kontrolnej
0’ 60’ 120’ 180’ p value*
Glucose [mmol/L] T2DM 8.51 ± 2.14 15.23 ± 2.97 16.61 ± 3.17 14.43 ± 3.21 0.000
Control 4.60 ± 0.50 6.30 ± 0.74 5.09 ± 0.60 4.58 ± 0.49 0.000
P value# 0.000 0.000 0.000 0.000
Insulin [uU/mL] T2DM 3.80 (2.60, 5.60) 19.70 (14.10, 26.20) 37.00 (20.28, 57.75) 13.50 (7.70, 22.20) 0.000
Control 3.45 (2.58, 4.50) 17.40 (8.40, 29.80) 16.00 (10.00, 29.60) 5.95 (4.13, 10.15) 0.000
P value# 0.359 0.407 0.000 0.002
FGF-21 [ng/mL] T2DM 2.27 ± 0.60 2.09 ± 0.55 2.01 ± 0.48 2.03 ± 0.52 0.000
Control 2.06 ± 0.39 2.00 ± 0.31 2.06 ± 0.37 2.17 ± 0.46 0.159
P value# 0.217 0.557 0.711 0.399
*p value represents the significance level of the repeated measure analysis for comparison of distributions of these characteristics in different OGTT time intervals;  
#p value represents the significance level of the Wilcoxon matched-paired test for comparison of distributions of these characteristics between T2DM group and 
control group; FGF-21 — fibroblast growth factor-21; OGTT — oral glucose tolerance test; T2DM — type 2 diabetes patients
Table II. Glucose, insulin and FGF-21 levels in OGTT before and after metformin
Tabela II. Stężenia glukozy, insuliny i FGF-21 podczas doustnego testu tolerancji glukozy przed i po podaniu metforminy
M0 M1 p value
Glucose [mmol/L] 0’ 8.51 ± 2.14 6.34 ± 1.46 0.000
60’ 15.23 ± 2.97 11.43 ± 2.85 0.000
120’ 16.61 ± 3.17 12.60 ± 3.13 0.000
180’ 14.43 ± 3.21 10.99 ± 3.46 0.000
Insulin [uU/mL] 0’ 3.80 (2.60, 5.60) 3.06 (1.98, 5.67) 0.121
60’ 17.40 (8.40, 29.80) 11.79 (4.59, 19.08) 0.013
120’ 16.00 (10.00, 29.60) 12.24 (9.36, 18.90) 0.107
180’ 13.50 (7.70, 22.20) 9.36 (5.85, 14.04) 0.007
FGF-21 [ng/mL] 0’ 2.27 ± 0.60 2.08 ± 0.54 0.006
60’ 2.09 ± 0.55 1.92 ± 0.50 0.016
120’ 2.01 ± 0.48 1.86 ± 0.50 0.010
180’ 2.03 ± 0.52 1.89 ± 0.50 0.007
HOMA-IR 1.35 (1.02, 2.01) 0.87 (0.58, 1.43) 0.001
FGF-21 — fibroblast growth factor-21; OGTT — oral glucose tolerance test
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increased at 180 minutes in T2DM. This implies that 
FGF-21 does not seem to be involved in the short-term 
regulation of glycaemia in humans, and the change in 
OGTT is delayed in nT2DM.
In some studies measuring plasma FGF-21, an ELISA 
kit has been used [13, 15]. It is the case that FGF-21 
values differ when measured by ELISA and by radio 
immunoassay, and the level of serum FGF-21 seems to 
be higher with radio immunoassay than with ELISA. 
This is probably due to the different methods. It might 
be that the antibody to FGF-21 is different, and that 
the antibody is specific for human FGF-21. Li et al. [16] 
evaluated FGF-21 levels in type 2 diabetic patients 
using radio immunoassay: FGF-21 concentrations 
were 1.81 ± 0.63 μg/L in newly diagnosed diabetic 
subjects and 1.52 ± 0.61 μg/L in a normal glycaemic 
control group when fasting. This is close to our results, 
although a difference exists.
Metformin is the most widely used drug in the treat-
ment of type 2 diabetes. However, the mechanism by 
which metformin acts is poorly understood. Metformin 
improves glucose and reduces insulin resistance per-
haps via the following mechanism: first, metformin 
activates AMP-activated protein kinase (AMPK), to 
reduce aggregation of lipid [17]. Second, recent find-
ings indicate that metformin treatment speeds up the 
transportation of GLUT1 [18]. Moreover, AMPK phos-
phorylation levels were increased by FGF-21 treatment 
in adipocytes as well as in white adipose tissue from ob/
ob mice [19]. The glucose uptake assay in 3T3-L1 adipo-
cytes indicated that the purified human FGF-21 could 
stimulate glucose uptake, and GLUT1 is the functional 
unit [20]. It has been reported that FGF-21 treatment (1 
μg/mL) led to a significant increase in GLUT1 mRNA 
and protein 3T3-L1 adipocytes [1]. Many studies have 
shown that HOMA-IR were positively associated with 
inflammatory parameters and metabolism character-
istics [21, 22]. In our study, after metformin, improved 
HOMA-IR was observed, and plasma FGF-21 levels 
decreased. No relations were found between FGF-21 
and HOMA-IR (data not shown). Thus, metformin may 
improve FGF-21 action through the AMPK pathway 
and transportation of GLUT1, and consequently allevi-
ate FGF-21 resistance and improve glucose and insulin 
sensitivity, and reduce plasma FGF-21 levels.
Our findings suggest that insulin might be an im-
portant factor for FGF-21 level, and the FGF-21 pathway 
might be a compensatory mechanism for impaired 
insulin action, but this needs further investigation.
Our results showed that no gender differences were 
observed at different time points in the control and the 
nT2DM group before the use of metformin, and this is in 
line with other reports [13, 23], But, in the nT2DM group, 
after one week of metformin treatment and with the sub-
jects divided into male and female groups, serum FGF-21 
levels decreased in the female group at different times of 
OGTT, differences that were not noted in the male group. 
It appears that metformin treatment  influences FGF-21 
concentration solely in females, but the number of males 
was small, and this needs further investigation.
Conclusions
In summary, our study shows that FGF-21 does not 
increase in the short term after glucose load and 
the magnitude of the plasma FGF-21 was blunted 
in the T2DM group more than in the control group. 
Administration of metformin for one week resulted 
in a significant decrease in FGF-21 at all OGTT times. 
Whether the change of plasma FGF-21 represents 
a compensatory effect, or a causative factor, in the 
development of glucose and insulin resistance is yet 
to be determined.
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